2163 related articles for article (PubMed ID: 15173093)
21. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.
Yu C; Rahmani M; Almenara J; Subler M; Krystal G; Conrad D; Varticovski L; Dent P; Grant S
Cancer Res; 2003 May; 63(9):2118-26. PubMed ID: 12727828
[TBL] [Abstract][Full Text] [Related]
22. The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis.
Zhang QL; Wang L; Zhang YW; Jiang XX; Yang F; Wu WL; Janin A; Chen Z; Shen ZX; Chen SJ; Zhao WL
Leukemia; 2009 Aug; 23(8):1507-14. PubMed ID: 19282831
[TBL] [Abstract][Full Text] [Related]
23. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
Nawrocki ST; Carew JS; Pino MS; Highshaw RA; Andtbacka RH; Dunner K; Pal A; Bornmann WG; Chiao PJ; Huang P; Xiong H; Abbruzzese JL; McConkey DJ
Cancer Res; 2006 Apr; 66(7):3773-81. PubMed ID: 16585204
[TBL] [Abstract][Full Text] [Related]
24. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
Pahler JC; Ruiz S; Niemer I; Calvert LR; Andreeff M; Keating M; Faderl S; McConkey DJ
Clin Cancer Res; 2003 Oct; 9(12):4570-7. PubMed ID: 14555532
[TBL] [Abstract][Full Text] [Related]
25. Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells.
Rahmani M; Yu C; Dai Y; Reese E; Ahmed W; Dent P; Grant S
Cancer Res; 2003 Dec; 63(23):8420-7. PubMed ID: 14679005
[TBL] [Abstract][Full Text] [Related]
26. Effects of antioxidants and caspase-3 inhibitor on the phenylethyl isothiocyanate-induced apoptotic signaling pathways in human PLC/PRF/5 cells.
Wu SJ; Ng LT; Lin CC
Eur J Pharmacol; 2005 Aug; 518(2-3):96-106. PubMed ID: 16054126
[TBL] [Abstract][Full Text] [Related]
27. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.
Lashinger LM; Zhu K; Williams SA; Shrader M; Dinney CP; McConkey DJ
Cancer Res; 2005 Jun; 65(11):4902-8. PubMed ID: 15930312
[TBL] [Abstract][Full Text] [Related]
28. The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells.
Pei XY; Dai Y; Grant S
Leukemia; 2003 Oct; 17(10):2036-45. PubMed ID: 14513055
[TBL] [Abstract][Full Text] [Related]
29. The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells.
Mandl-Weber S; Meinel FG; Jankowsky R; Oduncu F; Schmidmaier R; Baumann P
Br J Haematol; 2010 May; 149(4):518-28. PubMed ID: 20201941
[TBL] [Abstract][Full Text] [Related]
30. Brazilin induces apoptosis and G2/M arrest via inactivation of histone deacetylase in multiple myeloma U266 cells.
Kim B; Kim SH; Jeong SJ; Sohn EJ; Jung JH; Lee MH; Kim SH
J Agric Food Chem; 2012 Oct; 60(39):9882-9. PubMed ID: 22967175
[TBL] [Abstract][Full Text] [Related]
31. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
Yu C; Rahmani M; Conrad D; Subler M; Dent P; Grant S
Blood; 2003 Nov; 102(10):3765-74. PubMed ID: 12893773
[TBL] [Abstract][Full Text] [Related]
32. Evidence of a functional role for p21WAF1/CIP1 down-regulation in synergistic antileukemic interactions between the histone deacetylase inhibitor sodium butyrate and flavopiridol.
Rosato RR; Almenara JA; Yu C; Grant S
Mol Pharmacol; 2004 Mar; 65(3):571-81. PubMed ID: 14978235
[TBL] [Abstract][Full Text] [Related]
33. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
Meister S; Schubert U; Neubert K; Herrmann K; Burger R; Gramatzki M; Hahn S; Schreiber S; Wilhelm S; Herrmann M; Jäck HM; Voll RE
Cancer Res; 2007 Feb; 67(4):1783-92. PubMed ID: 17308121
[TBL] [Abstract][Full Text] [Related]
34. Sulindac-derived reactive oxygen species induce apoptosis of human multiple myeloma cells via p38 mitogen activated protein kinase-induced mitochondrial dysfunction.
Seo SK; Lee HC; Woo SH; Jin HO; Yoo DH; Lee SJ; An S; Choe TB; Park MJ; Hong SI; Park IC; Rhee CH
Apoptosis; 2007 Jan; 12(1):195-209. PubMed ID: 17136320
[TBL] [Abstract][Full Text] [Related]
35. The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells.
Cartee L; Wang Z; Decker RH; Chellappan SP; Fusaro G; Hirsch KG; Sankala HM; Dent P; Grant S
Cancer Res; 2001 Mar; 61(6):2583-91. PubMed ID: 11289135
[TBL] [Abstract][Full Text] [Related]
36. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells.
Qin JZ; Ziffra J; Stennett L; Bodner B; Bonish BK; Chaturvedi V; Bennett F; Pollock PM; Trent JM; Hendrix MJ; Rizzo P; Miele L; Nickoloff BJ
Cancer Res; 2005 Jul; 65(14):6282-93. PubMed ID: 16024630
[TBL] [Abstract][Full Text] [Related]
37. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1.
Gojo I; Zhang B; Fenton RG
Clin Cancer Res; 2002 Nov; 8(11):3527-38. PubMed ID: 12429644
[TBL] [Abstract][Full Text] [Related]
38. Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells.
Adachi M; Zhang Y; Zhao X; Minami T; Kawamura R; Hinoda Y; Imai K
Clin Cancer Res; 2004 Jun; 10(11):3853-62. PubMed ID: 15173094
[TBL] [Abstract][Full Text] [Related]
39. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.
Rocchi P; Tonelli R; Camerin C; Purgato S; Fronza R; Bianucci F; Guerra F; Pession A; Ferreri AM
Oncol Rep; 2005 Jun; 13(6):1139-44. PubMed ID: 15870934
[TBL] [Abstract][Full Text] [Related]
40. Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade.
Yerlikaya A; Erin N
Int J Mol Med; 2008 Dec; 22(6):817-23. PubMed ID: 19020781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
